Surveillance technologies are being used around the world to keep track of COVID-19 patients and whether or not they are following instructed guidelines, but many patients believe these surveillance methods are burdening fundamental rights.

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute (NCI), that evaluated the investigational compound entinostat, Syndax's class I HDAC inhibitor, plus exemestane in patients with advanced hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) breast cancer who have progressed on a non-steroidal aromatase inhibitor.

State Rep. Mark Baisley (R-Roxborough Park) issued a formal letter to request an investigation into alleged falsified death records done to inflate the state's COVID-19 death totals, KUSA-TV reported.

Men of color in the United States are at an increased risk of prostate cancer and other prostate conditions, and despite advances in diagnosis and treatment, disparities still remain.

As people continue to get sick and even die from COVID-19, a physicians and surgeons group shared concerns that some state governments are hoarding supplies of hydroxychloroquine (HCQ).

Sanofi U.S. today announced that it has reached an $11.85 million settlement agreement with the federal government to resolve an investigation relating to certain financial donations made in 2015 and 2016 to an independent charity patient assistance foundation that aided patients living with multiple sclerosis.

Advanced Sterilization Products (ASP) released today an interview with experts Ryan Lewis, M.D., Senior Director of Medical Affairs and Medical Safety, and Jeremy Yarwood, Vice President of Research and Development.

Innovative external urine collection device improves quality of care and reduce facility costs

Four real-world studies presented at the Annual Liver Meeting of the American Association for the Study of Liver Diseases

A large new study has found that an artery disease that mostly affects legs and feet is associated with increased use of opioids, the Society for Vascular Surgery reports.

BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direct Relief and the National Association of Community Health Centers (NACHC) recently honored six community health centers in the U.S. with the "Innovations in Care" award in recognition of their success in low-resource areas identifying and assisting vulnerable people to better manage complex chronic diseases and improve their health.

New research from the FH Foundation highlights that individuals at high risk for cardiovascular events, including those with familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD), experienced more heart attacks, strokes and other cardiovascular events when they were unable to obtain their prescribed PCSK9 inhibitor (PCSK9i), a cholesterol-lowering treatment.

Low-Dose Aspirin Continues to be the Gold Standard Treatment After Having a Heart Attack or Ischemic Stroke

Results showed that treatment with Emgality, when compared to placebo, resulted in lower levels of migraine-related disability and fewer restrictions on daily activities that are limited by migraine, such as relationships with family and friends, leisure time, productivity, concentration, energy and fatigue

Eli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients who are biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve.

For Second Year, Company Will Serve as Kidney Walk National Presenting Sponsor

Several citizens and organizations commented on an increased fear of diseases stemming from pollution related to hog farming in the area at the first of two meetings held by the North Carolina Department of Environmental Quality (DEQ) on proposed changes to three general animal operations permits.

Cleveland-based startup hires new CEO and prepares for market clearance

Phase 3 SPARTAN data served as basis for approval, which showed apalutamide decreased the risk of distant metastasis or death by 72 percent and improved median metastasis-free survival by more than two years

Epizyme, Inc. (Nasdaq: EPZM), a clinical-stage company developing novel epigenetic therapies, announced a comprehensive set of pipeline updates, including that the company has identified a path to submission for accelerated approval of tazemetostat for patients with relapsed and/or refractory follicular lymphoma (FL), both with and without EZH2 activating mutations.